Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Renalytix AI Announces Proposed Dual-listing on Nasdaq

May 18, 2020
NEW YORK, May 18, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has

RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression"

March 24, 2020
Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease   NEW YORK, March 24, 2020 /PRNewswire/ --  Renalytix AI plc (LSE: RENX),  the AIM-traded developer of

Medicare Sets National Price for KidneyIntelX™

December 3, 2019
NEW YORK, Dec. 3, 2019 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services ("CMS") has released the Final 2020 Clinical Laboratory Fee Schedule
Displaying 51 - 60 of 70